Exosomal miRNAs as Biomarkers for Prostate Cancer by Nina Pettersen Hessvik et al.
MINI REVIEW ARTICLE
published: 21 March 2013
doi: 10.3389/fgene.2013.00036
Exosomal miRNAs as biomarkers for prostate cancer
Nina Pettersen Hessvik 1,2, Kirsten Sandvig1,2,3 and Alicia Llorente1,2*
1 Department of Biochemistry, Institute for Cancer Research, Oslo University Hospital – The Norwegian Radium Hospital, Oslo, Norway
2 Centre for Cancer Biomedicine, Faculty of Medicine, University of Oslo, Oslo, Norway
3 Department of Biosciences, University of Oslo, Oslo, Norway
Edited by:
William Cho, Queen Elizabeth
Hospital, Hong Kong
Reviewed by:
Francesca Fanini, Istituto Scientifico
Romagnolo per lo Studio e la Cura dei
Tumori, Italy
Alessio Paone, Ohio State University,
USA
*Correspondence:
Alicia Llorente, Department of
Biochemistry, Oslo University
Hospital – The Norwegian Radium
Hospital, Ullernchausseen 70,
Montebello, 0379 Oslo, Norway.
e-mail: alicia.martinez.llorente@
rr-research.no
miRNAs are small non-coding RNAs that finely regulate gene expression in cells. Alterations
in miRNA expression have been associated with development of cancer, and miRNAs
are now being investigated as biomarkers for cancer as well as other diseases. Recently,
miRNAs have been found outside cells in body fluids. Extracellular miRNAs exist in differ-
ent forms – associated with Ago2 proteins, loaded into extracellular vesicles (exosomes,
microvesicles, or apoptotic bodies) or into high density lipoprotein particles. These extra-
cellular miRNAs are probably products of distinct cellular processes, and might therefore
play different roles. However, their functions in vivo are currently unknown. In spite of this,
they are considered as promising, non-invasive diagnostic, and prognostic tools. Prostate
cancer is the most common cancer in men in the Western world, but the currently used
biomarker (prostate specific antigen) has low specificity. Therefore, novel biomarkers are
highly needed. In this review we will discuss possible biological functions of extracellular
miRNAs, as well as the potential use of miRNAs from extracellular vesicles as biomarkers
for prostate cancer.
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INTRODUCTION
miRNAs are 19–23 nucleotides long non-coding RNAs that play
important gene-regulatory roles (Carrington and Ambros, 2003;
Bartel, 2004). These small RNAs downregulate gene expression
through incorporation into the RNA-induced silencing complex
(RISC), which then binds to partially complementary sites mainly
in the 3′untranslated region (3′UTR) of their mRNA targets
(Bartel, 2004). Depending on pairing complementarity, miRNAs
operate through translation repression, mRNA cleavage or desta-
bilization, or a combination of these routes (Lee et al., 1993;
Wightman et al., 1993; Hutvagner and Zamore, 2002; Song et al.,
2004; Lim et al., 2005). Several cellular processes like proliferation,
differentiation, and apoptosis are shown to be regulated by miR-
NAs (Bartel, 2004) and miRNAs are found aberrantly expressed
in many types of cancer (Calin et al., 2005; Iorio et al., 2005; Lu
et al., 2005; Volinia et al., 2006; Porkka et al., 2007; Croce, 2009).
Moreover, studies using knockout mice and transgenic mice over-
expressing certain miRNAs indicate that miRNAs do contribute
to cancer development (Mu et al., 2009; Hatley et al., 2010; Med-
ina et al., 2010). It has been shown that miRNAs can act both
as oncogenes and tumor suppressors, and that they participate in
cancer development by regulating cell cycle, cellular senescence,
DNA damage response, and apoptosis (Lima et al., 2011; Jansson
and Lund, 2012).
Prostate cancer is the most commonly diagnosed cancer in men
and the second leading cause of death among men with cancer in
the Western world (Ferlay et al., 2007; Jemal et al., 2009). A protein
mainly secreted by prostate cells, prostate specific antigen (PSA),
has been used as a blood-based biomarker for prostate cancer
for several decades. Even though PSA is a valuable tool, it lacks
specificity and is therefore not considered an optimal biomarker
(Nogueira et al., 2010). Thus, new and specific markers for prostate
cancer are highly needed. Several miRNA expression profiles have
been reported for prostate cancer, showing altered expression lev-
els in prostate cancer tissue compared to control tissue (Lu et al.,
2005; Volinia et al., 2006; Ozen et al., 2007; Porkka et al., 2007;
Ambs et al., 2008; Szczyrba et al., 2010). Importantly, miRNAs are
currently being investigated as prognostic and diagnostic tools for
prostate and other types of cancer (Sørensen and Ørntoft, 2009;
Kuner et al., 2013).
FORMS OF EXTRACELLULAR miRNAs
Recently, miRNAs have been identified in the medium from cul-
tured cells (Valadi et al., 2007) and in many body fluids like blood
(Chim et al., 2008; Lawrie et al., 2008), urine (Hanke et al., 2010),
saliva (Park et al., 2009), breast milk (Kosaka et al., 2010b; Weber
et al., 2010), and seminal plasma (Weber et al., 2010). Some of these
miRNAs appear in extracellular stable forms, which render them
interesting as biomarkers for cancer and other diseases. Extracel-
lular miRNA can be found in different forms (Figure 1); some
miRNAs are loaded into exosomes or microvesicles (Hunter et al.,
2008; Skog et al., 2008; Lasser et al., 2011; Gallo et al., 2012; Hessvik
et al., 2012), into apoptotic bodies (Zernecke et al., 2009), or into
high density lipoprotein particles (Vickers et al., 2011), whereas
others are associated with Ago2 proteins – proteins which are part
of RISC (Arroyo et al., 2011; Turchinovich et al., 2011). Common
to all these forms is that the miRNAs are not degraded by RNase
treatment (Valadi et al., 2007; Turchinovich et al., 2011). First, the
stability of extracellular miRNAs against RNases was thought to
be mainly due to incorporation of miRNAs into small extracel-
lular vesicles (Valadi et al., 2007; Hunter et al., 2008). However,
some reports have shown that most of the extracellular miRNAs
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FIGURE 1 | Extracellular miRNAs exist in different forms; loaded into exosomes/microvesicles, apoptotic bodies, or high density lipoprotein particles,
or associated with Ago2 proteins. MVB, multivesicular body.
in plasma and cell culture media are found outside vesicles, in
stable complexes with Ago2 proteins (Arroyo et al., 2011; Turchi-
novich et al., 2011), although a recent publication showed that the
majority of miRNAs in serum and saliva is enclosed in exosomes
(Gallo et al., 2012).
EXTRACELLULAR VESICLES
As mentioned, miRNAs have been found in several types of extra-
cellular vesicles. Extracellular vesicles are mainly classified based
on the different mechanism of release, but a consensus in the
terminology used to name these small vesicles is still lacking.
Normally, exosomes are defined as small membrane vesicles with
a diameter of 40–100 nm that are secreted when multivesicu-
lar bodies (MVBs) fuse with the plasma membrane (Pan et al.,
1985; Johnstone et al., 1987; Bobrie et al., 2011). Shedding vesi-
cles or microparticles are 0.1–1µm in diameter and formed by
budding from the plasma membrane (Cocucci et al., 2009). To
collectively describe both exosomes and shedding vesicles the term
microvesicles is often used (Cocucci et al., 2009), though this term
is sometimes also used to indicate either one of these types of
vesicles. A third type of extracellular vesicles is apoptotic bod-
ies, which are 1–4µm in diameter and formed during apoptosis
(Hristov et al., 2004; Zernecke et al., 2009). Recently, the term
extracellular vesicles has been used to describe these three classes
of vesicles as a group (Kalra et al., 2012).
POTENTIAL ROLES OF EXTRACELLULAR miRNAs
Whether the extracellular forms of miRNAs are simply waste
products from cells or have a biological function, such as par-
ticipating in intercellular communication is not yet clear. There
are reports showing increased level of miRNAs in blood upon
organ toxicity (Laterza et al., 2009; Zhang et al., 2010; Pritchard
et al., 2012), and this could of course represent waste products.
Nevertheless, since the various forms of extracellular miRNAs
are probably products of distinct cellular processes, they might
play different roles, and therefore it is important to distinguish
between them. Apoptotic bodies are by definition formed dur-
ing apoptosis. miRNA bound to Ago2 may be released from
cells upon apoptosis or necrosis (Turchinovich et al., 2011), but
it is not known if miRNA-Ago2 complexes also can be trans-
ported out of viable cells. This means that miRNAs bound to
Ago2 proteins and miRNAs incorporated into apoptotic bod-
ies might solely be by-products from dying cells or represent
a way for dying cells to communicate with neighboring cells.
They could represent a signal warning the organism about cellular
dysfunction.
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Shedding vesicles and exosomes are thought to be released by
viable cells, though it is not ruled out whether these vesicles also are
released by dying cells. Therefore, these vesicles have to a greater
extent been suggested to play a role in intercellular signaling (Val-
adi et al., 2007; Hunter et al., 2008). Indeed, it has been shown that
miRNAs can be transferred by exosomes from one cell to another
in vitro and result in downregulation of target genes in the recip-
ient cell (Kosaka et al., 2010a; Kogure et al., 2011; Mittelbrunn
et al., 2011; Montecalvo et al., 2012). This finding is intriguing
and indicates a role in intercellular communication which could
have a huge impact. Yet this remains to be shown in vivo. Interest-
ingly, it has been reported that injection of exosomes loaded with
siRNA into mice can result in specific gene knockdown in certain
cells (Alvarez Erviti et al., 2011). It has been questioned whether
the concentration of exosomes in biological fluids is high enough
to play a role in intercellular communication, but this does not
exclude a role in autocrine or paracrine signaling (Turchinovich
et al., 2011; Sverdlov, 2012). Exosomes probably exert their effect
on neighboring cells, and thereby participate in creating a specific
microenvironment. In this scenario, the exosomes found in body
fluids would only be residual amounts, representing a secondary
effect.
In addition to their conventional role in post-transcriptional
gene regulation, a new role for miRNAs as signaling molecules
has recently been described by two independent groups. Interest-
ingly, extracellular let-7 was shown to activate Toll-like receptor 7
in neurons and induce neurodegeneration (Lehmann et al., 2012).
By another group, exosomal miR-21 and miR-29a was shown to
activate Toll-like receptor 7 and 8 in immune cells, triggering
a prometastatic inflammatory response that may lead to tumor
growth and metastasis (Fabbri et al., 2012). Thus, extracellular
miRNAs could be important regulators of tumor microenviron-
ment as well as exacerbate CNS damage, through agonistic effect
on Toll-like receptor 7 and 8.
Another possible role for miRNAs in exosomes and MVBs is
that they might function together with the RNAi machinery. RISC
proteins have been shown to be associated with MVBs and exo-
somes (Gibbings et al., 2009; Lee et al., 2009). Moreover, blocking
MVB formation by depletion of ESCRT (endosomal sorting com-
plex required for transport) components has been reported to
result in impaired miRNA silencing, indicating a role in RNAi
dynamics (Gibbings et al., 2009; Lee et al., 2009).
ARE miRNAs SORTED INTO EXOSOMES?
Another debated issue in the field is whether miRNAs are sorted
into MVBs and exosomes or not. Several reports have shown that
certain miRNAs are selectively identified or expressed at a higher
level in exosomes than in parent cells (Valadi et al., 2007; Ohshima
et al., 2010; Kogure et al., 2011; Mittelbrunn et al., 2011; Hessvik
et al., 2012), indicating a sorting of miRNAs into MVBs. The
opposite situation has also been reported; for example one study
showed that only 2% of the most abundant miRNA in a breast
cancer cell line, miR-720, was found extracellularly, whereas many
other miRNAs were presented at comparable levels in the cellular
and extracellular populations (Pigati et al., 2010). The findings
that certain miRNAs are either enriched in exosomes or retained
in cells, indicate that exosomal miRNAs are not simply unsorted
waste products from cells. The mechanisms controlling the selec-
tion of miRNAs into exosomes or the retention of miRNAs inside
cells still remain unknown. Though, it cannot be excluded that the
higher expression level of certain miRNAs in exosomes is due to
shielding of miRNAs from degradation by exosome membranes,
and not due to a sorting mechanism. Moreover, Kim et al. (2012)
recently reported that small RNAs with low GC content can be lost
during RNA isolation from samples with low RNA content, indi-
cating methodological challenges when working with extracellular
miRNAs.
Higher levels of exosomes are found in plasma from cancer
patients compared to control individuals (Rabinowits et al., 2009;
Tavoosidana et al., 2011), suggesting that cancer cells secrete more
exosomes than non-cancerous cells. Therefore, measuring exoso-
mal miRNAs could result in less background from normal cells,
and they might then serve as superior biomarkers compared to
other extracellular miRNAs. However, the currently used protocols
for exosome isolation are extensive and time-consuming. New and
faster isolation methods need to be established before exosomal
miRNAs can be used in routine diagnostics.
miRNAs AND PROSTATE CANCER
The first profiling of miRNAs in prostate cancer was published
in 2007 (Porkka et al., 2007). In this study prostate cancer cell
lines and prostate tissue from both benign prostatic hyperplasia
and prostate cancer patients were examined. Today, the miRNA
expression in prostate cancer has been published in more than 100
reports, showing promising results for miRNAs as tissue-based
biomarkers for this disease (Catto et al., 2011). Measurement of
extracellular miRNAs obtained from biological fluids constitutes
a non-invasive approach for cancer detection and may there-
fore be preferable. Indeed, several studies (Table 1, and discussed
below) have investigated the miRNA profile in serum/plasma from
prostate cancer patients, pointing toward the use of miRNAs as
blood-based biomarkers (Mitchell et al., 2008; Lodes et al., 2009;
Brase et al., 2011; Moltzahn et al., 2011).
In the first study, the level of six miRNAs in serum samples
from 25 patients with metastatic prostate cancer and 25 healthy
controls was analyzed. The authors found that miR-141 was over-
expressed in the prostate cancer group compared to the control
group, and that this miRNA had the greatest differential expres-
sion among the six tested miRNAs (Mitchell et al., 2008). Later, 667
miRNAs in serum samples from patients with metastatic (n= 7)
or localized prostate cancer (n= 14) were screened. In this study
69 miRNAs were found to be higher expressed in the metasta-
tic tumor group compared to the primary cancer group. Five
of the upregulated miRNAs (miR-375, miR-9∗, miR-141, miR-
200b, and miR-516a-3p) were further validated, resulting in the
identification of miR-375 and miR-141 as the best markers for
high risk prostate cancer (Brase et al., 2011). Another study ana-
lyzed the expression of miR-21, miR-141, and miR-221 in plasma
from patients with localized/local advanced (n= 26) or metastatic
(n= 25) prostate cancer and healthy controls (n= 20). A higher
expression level of miR-21 and miR-221,but not statistically signif-
icant for miR-141, was observed in plasma from prostate cancer
patients compared to controls. Still, all three miRNAs were sig-
nificantly higher in patients with metastatic prostate cancer than
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Table 1 | Studies of extracellular miRNAs in body fluids from prostate cancer patients.
Promising
miRNA
Deregulation Body fluid Study design Number of
participants
Reference
let-7a ↑ Whole blood PCa vs. healthy controls 83 Heneghan et al. (2010)
let-7c ↓ Plasma PCa vs. BPH and healthy controls Screening: 42 Chen et al. (2012)
Validation: 178
let-7e ↓ Plasma PCa vs. BPH and healthy controls Screening: 42 Chen et al. (2012)
Validation: 178
let-7i ↑ Serum Localized PCa vs. BPH and healthy controls 83 Mahn et al. (2011)
miR-16 ↑ Serum Stage 3 and 4 PCa patients vs. healthy controls 13 Lodes et al. (2009)
miR-20a ↑ Plasma PCa: high risk vs. intermediate risk vs. low risk 82 Shen et al. (2012)
miR-21 ↑ Plasma PCa: high risk vs. intermediate risk vs. low risk 82 Shen et al. (2012)
↑ Plasma Metastatic PCa vs. localized/local advanced PCa
vs. healthy controls
71 Yaman Agaoglu et al.
(2011)
↑ Serum Hormone-refractory PCa vs. androgen
dependent PCa vs. localized PCa vs. BPH
56 Zhang et al. (2011)
miR-24 ↓ Serum PCa vs. healthy controls 48 Moltzahn et al. (2011)
miR-26a ↑ Serum Localized PCa vs. BPH and healthy controls 83 Mahn et al. (2011)
miR-26b ↓ Serum PCa vs. healthy controls 48 Moltzahn et al. (2011)
miR-30c ↓ Plasma PCa vs. BPH and healthy controls Screening: 42 Chen et al. (2012)
Validation: 178
↓ Serum PCa vs. healthy controls 48 Moltzahn et al. (2011)
miR-34b ↑ Serum Stage 3 and 4 PCa patients vs. healthy controls 13 Lodes et al. (2009)
miR-92a ↑ Serum Stage 3 and 4 PCa patients vs. healthy controls 13 Lodes et al. (2009)
miR-92b ↑ Serum Stage 3 and 4 PCa patients vs. healthy controls 13 Lodes et al. (2009)
miR-93 ↑ Serum PCa vs. healthy controls 48 Moltzahn et al. (2011)
miR-103 ↑ Serum Stage 3 and 4 PCa patients vs. healthy controls 13 Lodes et al. (2009)
miR-106a ↑ Serum PCa vs. healthy controls 48 Moltzahn et al. (2011)
miR-107 ↑ Plasma
(microvesicles)
PCa vs. healthy controls Screening: 106 Bryant et al. (2012)
↑ Urine (cells) PCa vs. healthy controls 135 Bryant et al. (2012)
↑ Serum Stage 3 and 4 PCa patients vs. healthy controls 13 Lodes et al. (2009)
miR-130b ↑ Plasma
(microvesicles)
PCa vs. healthy controls Screening: 106 Bryant et al. (2012)
miR-141 ↑ Serum Metastatic PCa vs. localized PCa Screening: 21 Brase et al. (2011)
Validation: 116
↑ Plasma
(microvesicles)
PCa vs. healthy controls Screening: 106 Bryant et al. (2012)
↑ Serum
(microvesicles)
Metastatic vs. localized PCa Validation: 119 Bryant et al. (2012)
↑ Serum Metastatic PCa vs. healthy controls 50 Mitchell et al. (2008)
↑ Serum Metastatic PCa vs. healthy controls 50 Selth et al. (2012)
↑ Plasma Metastatic PCa vs. localized/local advanced PCa
vs. healthy controls
71 Yaman Agaoglu et al.
(2011)
(Continued)
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Table 1 | Continued
Promising
miRNA
Deregulation Body fluid Study design Number of
participants
Reference
miR-145 ↓ Whole blood PCa vs. healthy controls 83 Heneghan et al. (2010)
↑ Plasma PCa: high risk vs. intermediate risk vs. low risk 82 Shen et al. (2012)
miR-155 ↓ Whole blood PCa vs. healthy controls 83 Heneghan et al. (2010)
miR-181a-2* ↓ Plasma
(microvesicles)
PCa vs. healthy controls Screening: 106 Bryant et al. (2012)
miR-195 ↑ Serum Localized PCa vs. BPH and healthy controls 83 Mahn et al. (2011)
miR-197 ↑ Serum Stage 3 and 4 PCa patients vs. healthy controls 13 Lodes et al. (2009)
miR-221 ↑ Plasma PCa: high risk vs. intermediate risk vs. low risk 82 Shen et al. (2012)
↑ Plasma Metastatic PCa vs. localized/local advanced PCa
vs. healthy controls
71 Yaman Agaoglu et al.
(2011)
↑ Plasma PCa vs. healthy controls 43 Zheng et al. (2012)
miR-223 ↓ Serum PCa vs. healthy controls 48 Moltzahn et al. (2011)
miR-298 ↑ Serum Metastatic PCa vs. healthy controls 50 Selth et al. (2012)
miR-301a ↑ Plasma
(microvesicles)
PCa vs. healthy controls Screening: 106 Bryant et al. (2012)
miR-326 ↑ Plasma
(microvesicles)
PCa vs. healthy controls Screening: 106 Bryant et al. (2012)
miR-328 ↑ Serum Stage 3 and 4 PCa patients vs. healthy controls 13 Lodes et al. (2009)
miR-331-3p ↑ Plasma
(microvesicles)
PCa vs. healthy controls Screening: 106 Bryant et al. (2012)
miR-346 ↑ Serum Metastatic PCa vs. healthy controls 50 Selth et al. (2012)
miR-375 ↑ Serum Metastatic PCa vs. localized PCa Screening: 21 Brase et al. (2011)
Validation: 116
↑ Serum
(microvesicles)
Metastatic vs. localized PCa Validation: 119 Bryant et al. (2012)
↑ Serum Metastatic PCa vs. healthy controls 50 Selth et al. (2012)
miR-432 ↑ Plasma
(microvesicles)
PCa vs. healthy controls Screening: 106 Bryant et al. (2012)
miR-485-3p ↑ Serum Stage 3 and 4 PCa patients vs. healthy controls 13 Lodes et al. (2009)
miR-486-5p ↑ Serum Stage 3 and 4 PCa patients vs. healthy controls 13 Lodes et al. (2009)
miR-574-3p ↑ Plasma
(microvesicles)
PCa vs. healthy controls Screening: 106 Bryant et al. (2012)
↑ Urine (cells) PCa vs. healthy controls 135 Bryant et al. (2012)
↑ Serum Stage 3 and 4 PCa patients vs. healthy controls 13 Lodes et al. (2009)
miR-622 ↑ Plasma PCa vs. BPH and healthy controls Screening: 42 Chen et al. (2012)
Validation: 178
miR-625* ↑ Plasma
(microvesicles)
PCa vs. healthy controls Screening: 106 Bryant et al. (2012)
miR-636 ↑ Serum Stage 3 and 4 PCa patients vs. healthy controls 13 Lodes et al. (2009)
miR-640 ↑ Serum Stage 3 and 4 PCa patients vs. healthy controls 13 Lodes et al. (2009)
miR-766 ↑ Serum Stage 3 and 4 PCa patients vs. healthy controls 13 Lodes et al. (2009)
(Continued)
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Table 1 | Continued
Promising
miRNA
Deregulation Body fluid Study design Number of
participants
Reference
miR-874 ↑ Serum PCa vs. healthy controls 48 Moltzahn et al. (2011)
miR-885-5p ↑ Serum Stage 3 and 4 PCa patients vs. healthy controls 13 Lodes et al. (2009)
miR-1207-5p ↑ Serum PCa vs. healthy controls 48 Moltzahn et al. (2011)
miR-1274a ↑ Serum PCa vs. healthy controls 48 Moltzahn et al. (2011)
miR-1285 ↑ Plasma PCa vs. BPH and healthy controls Screening: 42 Chen et al. (2012)
Validation: 178
miR-2110 ↑ Plasma
(microvesicles)
PCa vs. healthy controls Screening: 106 Bryant et al. (2012)
miRNAs ordered by increasing name number. PCa, prostate cancer; BPH, benign prostatic hyperplasia. Asterisks are part of the miRNA names.
in patients with localized/local advanced disease (Yaman Agaoglu
et al., 2011). In a study by Lodes et al. 547 miRNAs were screened,
15 miRNAs (miR-16, -92a, -103, -107, -197, -34b, -328, -485-3p,
-486-5p, -92b, -574-3p, -636, -640, -766, -885-5p) were found to be
overexpressed in serum from stage 3 and 4 prostate cancer patients
(n= 5) compared to eight healthy controls. They also showed a
slightly elevated level of miR-141 in stage 3 and 4 prostate can-
cer patient serum (Lodes et al., 2009). Selth et al. analyzed the
expression of 10 miRNAs in serum from patients with metastatic
castration-resistant prostate cancer (n= 25) and healthy controls
(n= 25). They found that miR-141, miR-298, miR-346, and miR-
375 were upregulated in serum from prostate patients compared
with controls (Selth et al., 2012). Though these independent stud-
ies point toward plasma/serum-derived miR-141 and miR-375
as biomarkers, Mahn et al. (2011) did not succeed in detecting
miR-141 in serum samples.
In the study by Mahn et al. the expression of four miRNAs
in serum from 37 patients with localized prostate cancer, eight
with metastatic prostate cancer, 18 with benign prostatic hyper-
plasia, and 20 healthy controls was analyzed. They found miR-26a,
miR-195, and let-7i to be upregulated in patients with prostate
cancer compared with patients with benign prostatic hyperplasia.
Moreover, they also showed that miR-26a levels could discriminate
patients with prostate cancer from patients with benign prostatic
hyperplasia (Mahn et al., 2011). Another report showed results
from screening of 384 miRNAs in serum from 36 prostate cancer
patients and 12 healthy controls. Five miRNAs (miR-874, -1274a, -
1207-5p, -93, and -106a) were identified to be upregulated and four
(miR-223, -26b, -30c, and -24) downregulated in cancer patients
compared to controls (Moltzahn et al., 2011). Heneghan et al.
(2010) analyzed the expression of seven miRNAs and found a
decreased level of miR-145 and miR-155 and an increased level
of let-7a in whole blood from prostate cancer patients (n= 20)
compared to healthy controls (n= 63).
Although a higher level of miR-21 in plasma from prostate
cancer patients compared to controls has been observed (Yaman
Agaoglu et al., 2011), Zhang et al. did not find a significant dif-
ference in the level of serum-derived miR-21 between patients
with benign prostatic hyperplasia (n= 6), localized (n= 20),
and androgen dependent prostate cancer (n= 20). Still, higher
expression of miR-21 was detected in patients with hormone-
refractory prostate cancer (n= 10), especially in patients resis-
tant to docetaxel-based chemotherapy, suggesting a potential role
for miRNAs as markers for disease progression and response
to treatment (Zhang et al., 2011). In another study, the level
of miR-221 in plasma samples from healthy controls (n= 20),
androgen dependent (n= 15), and androgen independent (n= 8)
prostate cancer patients was analyzed. In accordance with the
findings by Yaman Agaoglu et al. the authors observed increased
expression of miR-221 in plasma samples from prostate can-
cer patients compared with healthy controls, whereas the level
of miR-221 was increased in androgen dependent compared to
androgen independent prostate cancer patients (Zheng et al.,
2012).
Chen et al. screened the miRNA expression in plasma from
25 prostate cancer patients and 17 patients with benign prostatic
hyperplasia and validated candidate miRNAs in a larger indepen-
dent cohort (80 prostate cancer patients, 44 patients with benign
prostatic hyperplasia, and 54 healthy controls). These authors
showed that five miRNAs (let-7c, let-7e, miR-30c, miR-622, and
miR-1285) could differentiate patients with prostate cancer from
patients with benign prostatic hyperplasia and healthy controls.
They suggested that a panel of the five described miRNAs could
distinguish these patient groups from each other with higher sen-
sitivity and specificity compared to one single miRNA (Chen et al.,
2012). Another group also suggested a combination of several miR-
NAs as biomarker after analyzing miRNA levels in plasma samples
from 82 prostate cancer patients with varied aggressiveness. In
this report the combination of miR-20a, miR-21, miR-145, and
miR-221 was shown to distinguish prostate cancer patients with
high risk of aggressiveness from those with low risk (Shen et al.,
2012).
Neither of the mentioned studies describes in which form the
extracellular miRNAs were packaged. In only one study miRNAs
from plasma- and serum-derived microvesicles were analyzed,
though the vesicles were not well characterized. Eleven miRNAs
were found to be differently expressed in prostate cancer patients
compared to healthy controls (miR-107, -130b, -141, -181a-2∗,
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-2110, -301a, -326, -331-3p, -432, -574-3p, and -625∗), and 16
miRNAs were upregulated in patients with metastases compared
to patients without metastases. The association of miR-141 and
miR-375 with metastatic prostate cancer was also confirmed. The
authors selected five miRNAs that were analyzed in urine samples,
showing that miR-107 and miR-574-3p were found in higher con-
centrations in the urine of men with prostate cancer compared
with healthy controls. However, these miRNAs were not really
extracellular, since cell pellets from urine were used in this part of
the study (Bryant et al., 2012). Recently, we described the miRNA
profile in exosomes from the PC-3 metastatic prostate cancer cell
line. Among the aforementioned miRNAs suggested as biomarker
candidates in clinical studies, we identified 36 in exosomes from
PC-3 cells (miR-141, -9∗, -200b, -21, -221, -16, -92a, -103, -107,
-197, -92b, -574-3p, -885-5p, -298, -26a, -1274a, -106a, -26b, -30c,
-24, let-7i, let-7a, let-7c, let-7e, miR-1285, -20a, -107, -130b, -301a,
-331-3p, -625, -485-3p, -874, -155, -181a-2∗, and -326) (Hessvik
et al., 2012).
As described, an emerging amount of evidence points toward
a potential use of blood-based miRNAs as diagnostic and prog-
nostic biomarkers for prostate cancer (Table 1). Nevertheless, the
data from the clinical studies are to some extent inconsistent. This
may not be surprising due to the fact that these studies differ with
respect to experimental design and patient cohort. Most of these
studies are small-scale, with varying degree of patient description
and few are focusing on cancer-related death or progression free
survival as endpoints. At least one study included patients under
treatment with chemotherapy, therefore it is uncertain whether
the altered miRNA levels were due to the chemotherapy or due
to the tumor itself (Lodes et al., 2009). In addition, different plat-
forms have been used to quantify miRNA levels, which also could
explain some of the conflicting data. High throughput platforms
always have biases and confirmation with a secondary analytical
approach, such as RT-qPCR, should be performed to validate the
results. Isolation of extracellular miRNAs using different methods
can contribute to variation due to low recovery of certain miRNA
species, and quantification of extracellular miRNAs are challeng-
ing due to lack of standards for quality control, normalization, and
statistical analysis. Together, these factors might explain most of
the conflicting results.
Blood is the body fluid that traditionally has been used as the
main source of cancer biomarkers, though the use of urine in can-
cer diagnosis and prognosis is growing. Choosing urine as a source
of biomarkers has several advantages compared to blood; it is non-
invasive, easily obtained in large quantities, and the composition
of urine is less complex. Particularly important for prostate cancer
is the fact that the composition of urine reflects alterations in the
urogenital system. However, dilution of the miRNAs could be a
possible drawback with the use of urine as a source of biomarkers.
To our knowledge there are currently no publications describing
the miRNA content of urinary exosomes in prostate cancer.
CONCLUSION
Intensive research is put into the hunt for new diagnostic and
prognostic tools for prostate cancer. Representing a non-invasive
approach, measurement of extracellular miRNAs in blood, urine,
or other biological fluids might turn out as a valuable strat-
egy. Studies on blood-based miRNAs as biomarkers for prostate
cancer are emerging, but most of these are small-scale, vary in
methodology, and lack a characterization of the form in which the
extracellular miRNAs are found. Standards for miRNA quantifi-
cation need to be established and larger validation studies need
to be performed before conclusions can be drawn on the diag-
nostic potential of specific miRNAs. It might be important to
distinguish between different forms of extracellular miRNAs, both
for diagnosis and for understanding possible biological functions.
More and large-scale studies on exosomal miRNAs in biologi-
cal fluids from prostate cancer patients and healthy controls are
therefore needed. Although there is still very limited knowledge
about the biological roles of extracellular miRNAs and extracellu-
lar vesicles, they are currently emerging as an important source of
biomarkers.
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